101 College St. Rendering
Currently, the demand for lab space exceeds the available inventory. In response to this growing demand, Carter Winstanley is adding to his development project efforts with 101 College St. Previously, 100 College St. was completed as part of the Downtown Crossing Project that is knitting the medical district with the downtown area. Currently, 100 College St. is fully occupied with researchers from Alexion (although they moved their administrative offices to Boston, the scientists remained in New Haven) and Yale University researchers.
Biomed & Life Sciences
2nd Largest Bioscience Hub in New England
With nearly 60,000 employees working in this industry cluster, including healthcare workers, it is one of the strongest in the region. With world class institutional and academic assets to leverage, this region has become a focus of biomedical expertise and development.
To support the development of convenient, accurate diagnostics and potential therapeutics for COVID-19, we can anticipate an increase in NIH funding to Yale University. NIH Funding in 2020 was $568M. Given the higher costs of care associated with patients with underlying health issues, continued R&D is needed for existingdiseases. We have a number of early-stage and mature bioscience companies working on treatmentsfor co-morbidities such as diabetes, high blood pressure, cancer and more.
In 2020, the following Greater New Haven companies received funding from the National Institute of Public Health:
-
ALLYX THERAPEUTICS INC.
-
CAROGEN CORPORATION
-
CENTER FOR PROGRESSIVE RECOVERY, LLC
-
CONNECTICUT AGRICULTURAL EXPERIMENT STATION
-
CORNOVUS PHARMACEUTICALS, INC.
-
CYBREXA, INC.
-
HASKINS LABORATORIES, INC.
-
JOHN B. PIERCE LABORATORY, INC.
-
L2 DIAGNOSTICS, LLC
-
OUI THERAPEUTICS, LLC
-
PROTEOWISE, INC.
-
RENETX BIO, INC.
-
SOUTHERN CONNECTICUT STATE UNIVERSITY
-
THETIS PHARMACEUTICALS, LLC
-
VIRSCIO, INC.
-
YALE UNIVERSITY